793695-66-6

Basic information

• Product Name: (1'S,2'R,3'S,4'R,5'S)-4'-[6-(5-chloro-2-methoxybenzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester
• Synonyms: (1'S,2'R,3'S,4'R,5'S)-4'-[6-(5-chloro-2-methoxybenzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester
• CAS NO: 793695-66-6
• Molecular Weight: 548.426
• Mol File: 793695-66-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (1'S,2'R,3'S,4'R,5'S)-4'-[6-(5-chloro-2-methoxybenzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1'S,2'R,3'S,4'R,5'S)-4'-[6-(5-chloro-2-methoxybenzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester(793695-66-6)
• EPA Substance Registry System: (1'S,2'R,3'S,4'R,5'S)-4'-[6-(5-chloro-2-methoxybenzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester(793695-66-6)

Safety Data

• Hazardous Substances Data: 793695-66-6(Hazardous Substances Data)

Upstream product

• 793695-59-7 ethyl (1S,2R,3S,4S,5S)-2,3-O-isopropylidene-4-hydroxybicyclo[3.1.0]hexane-1-carboxylate 
• 5451-40-1 2,6 dichloropurine 
• 181473-92-7 1-(5-chloro-2-methoxyphenyl)methanamine 
• 793695-60-0 ethyl (1'S,2'R,3'S,4'R,5'S)-4'-(2,6-dichloropurin-9-yl)-2',3'-O-(isopropylidene)bicyclo[3.1.0]hexane-1'-carboxylate 

Downstream Products

• 1078503-57-7 (1'S,2'R,3'S,4'S,5'S)-4'-[2-chloro-6-(5-chloro-2-methoxybenzylamino)purin-9-yl]-2',3'-dihydroxybicyclo[3.1.0]hexane-1'-carboxylic acid ethyl ester 

Relevant articles and documents

PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS

Disclosed are (N)-methanocarba adenine nucleosides of the formula: [Formula] as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.